Published in HIV Med on April 01, 2006
Acquisition of GB virus type C and lower mortality in patients with advanced HIV disease. Clin Infect Dis (2012) 1.59
GB virus type C interactions with HIV: the role of envelope glycoproteins. J Viral Hepat (2009) 1.41
GB virus C: the good boy virus? Trends Microbiol (2012) 1.39
An 85-aa segment of the GB virus type C NS5A phosphoprotein inhibits HIV-1 replication in CD4+ Jurkat T cells. Proc Natl Acad Sci U S A (2006) 1.23
AIDS alters the commensal plasma virome. J Virol (2013) 1.17
Viruses within the Flaviviridae decrease CD4 expression and inhibit HIV replication in human CD4+ cells. J Immunol (2009) 1.10
GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy. AIDS (2009) 1.09
CCL3L1 copy number is a strong genetic determinant of HIV seropositivity in Caucasian intravenous drug users. J Infect Dis (2010) 1.00
GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates. J Immunol (2010) 0.99
GB virus C coinfections in west African Ebola patients. J Virol (2014) 0.99
Effect of primer selection on estimates of GB virus C (GBV-C) prevalence and response to antiretroviral therapy for optimal testing for GBV-C viremia. J Clin Microbiol (2006) 0.99
The National Heart, Lung, and Blood Institute Recipient Epidemiology and Donor Evaluation Study (REDS-III): a research program striving to improve blood donor and transfusion recipient outcomes. Transfusion (2013) 0.95
Role of GB virus C in modulating HIV disease. Expert Rev Anti Infect Ther (2012) 0.95
GB virus C particles inhibit T cell activation via envelope E2 protein-mediated inhibition of TCR signaling. J Immunol (2013) 0.94
Characterization of a peptide domain within the GB virus C NS5A phosphoprotein that inhibits HIV replication. PLoS One (2008) 0.93
GB virus C infection is associated with altered lymphocyte subset distribution and reduced T cell activation and proliferation in HIV-infected individuals. PLoS One (2012) 0.92
Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication. Virology (2012) 0.90
Characterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding. J Virol (2006) 0.89
Genotyping and infection rate of GBV-C among Iranian HCV- infected patients. Hepat Mon (2010) 0.89
Human pegivirus RNA is found in multiple blood mononuclear cells in vivo and serum-derived viral RNA-containing particles are infectious in vitro. J Gen Virol (2014) 0.88
GB virus C viremia is associated with higher levels of double-negative T cells and lower T-cell activation in HIV-infected individuals receiving antiretroviral therapy. J Infect Dis (2012) 0.88
Arteriviruses, Pegiviruses, and Lentiviruses Are Common among Wild African Monkeys. J Virol (2016) 0.87
Durable sequence stability and bone marrow tropism in a macaque model of human pegivirus infection. Sci Transl Med (2015) 0.86
Coinfecting viruses as determinants of HIV disease. Curr HIV/AIDS Rep (2009) 0.86
GB virus C infection and B-cell, natural killer cell, and monocyte activation markers in HIV-infected individuals. AIDS (2013) 0.86
The natural history of non-human GB virus C in captive chimpanzees. J Gen Virol (2010) 0.86
GB virus type C infection polarizes T-cell cytokine gene expression toward a Th1 cytokine profile via NS5A protein expression. J Infect Dis (2012) 0.83
The GB virus C (GBV-C) NS3 serine protease inhibits HIV-1 replication in a CD4+ T lymphocyte cell line without decreasing HIV receptor expression. PLoS One (2012) 0.81
Transmission of GB virus type C via transfusion in a cohort of HIV-infected patients. J Infect Dis (2012) 0.81
Cell-Mediated Immunity in Elite Controllers Naturally Controlling HIV Viral Load. Front Immunol (2013) 0.80
HIV-1 fusion is blocked through binding of GB Virus C E2-derived peptides to the HIV-1 gp41 disulfide loop [corrected]. PLoS One (2013) 0.79
Large scale screening of human sera for HCV RNA and GBV-C RNA. J Med Virol (2013) 0.78
Intra-host diversity and emergence of unique GBV-C viral lineages in HIV infected subjects in central China. PLoS One (2012) 0.78
A novel T cell evasion mechanism in persistent RNA virus infection. Trans Am Clin Climatol Assoc (2014) 0.77
Role of GB virus C in HIV-1-infected and hepatitis C virus-infected hemophiliac children and adolescents. J Acquir Immune Defic Syndr (2012) 0.77
Inhibition of HIV type 1 replication by human T lymphotropic virus types 1 and 2 Tax proteins in vitro. AIDS Res Hum Retroviruses (2013) 0.77
Cytokine/chemokine expression associated with Human Pegivirus (HPgV) infection in women with HIV. J Med Virol (2017) 0.76
GB Virus C (GBV-C) Infection in Hepatitis C Virus (HCV) Seropositive Women with or at Risk for HIV Infection. PLoS One (2014) 0.76
Bayesian analysis and classification of two enzyme-linked immunosorbent assay tests without a gold standard. Stat Med (2013) 0.75
A copula model for bivariate hybrid censored survival data with application to the MACS study. Lifetime Data Anal (2010) 0.75
High HPgV replication is associated with improved surrogate markers of HIV progression. PLoS One (2017) 0.75
Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet (1999) 14.96
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A (1999) 14.16
Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med (1987) 7.82
Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med (2001) 3.98
A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med (1989) 2.78
Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol (2000) 2.50
Association between fulminant hepatic failure and a strain of GBV virus C. Lancet (1996) 1.82
Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. JAMA (1988) 1.76
Parvovirus B19 infection in human immunodeficiency virus type 1-infected persons failing or intolerant to zidovudine therapy. J Infect Dis (1993) 1.63
In vitro assay to demonstrate high-level erythromycin resistance of a clinical isolate of Treponema pallidum. Antimicrob Agents Chemother (1988) 1.46
Full-length GB virus C (Hepatitis G virus) RNA transcripts are infectious in primary CD4-positive T cells. J Virol (2000) 1.29
GB virus C/hepatitis G virus infection: a favorable prognostic factor in human immunodeficiency virus-infected patients? J Infect Dis (1998) 1.27
Elevated phenotypic switching and drug resistance of Candida albicans from human immunodeficiency virus-positive individuals prior to first thrush episode. J Clin Microbiol (2000) 1.25
Neutralizing antibody to hepatitis A virus in immune serum globulin and in the sera of human recipients of immune serum globulin. Gastroenterology (1985) 1.24
Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol (1997) 1.24
Neutralization escape mutants define a dominant immunogenic neutralization site on hepatitis A virus. J Virol (1987) 1.22
Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology (1997) 1.21
Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat (2007) 1.21
Surreptitious hepatitis C virus (HCV) infection detected in the majority of patients with cryptogenic chronic hepatitis and negative HCV antibody tests. J Infect Dis (1997) 1.19
Identification of an immunodominant antigenic site involving the capsid protein VP3 of hepatitis A virus. Proc Natl Acad Sci U S A (1988) 1.18
In vivo replication and reversion to wild type of a neutralization-resistant antigenic variant of hepatitis A virus. J Infect Dis (1990) 1.16
A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. Gastroenterology (1997) 1.13
Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat (2006) 1.12
Distribution of hepatitis C virus (HCV) RNA in whole blood and blood cell fractions: plasma HCV RNA analysis underestimates circulating virus load. J Infect Dis (1997) 1.11
Direct detection of hepatitis C virus (HCV) RNA from whole blood, and comparison with HCV RNA in plasma and peripheral blood mononuclear cells. J Med Virol (1995) 1.10
Association of hypocholesterolaemia with hepatitis C virus infection in HIV-infected people. HIV Med (2004) 1.10
Characterization of hepatitis G virus (GB-C virus) particles: evidence for a nucleocapsid and expression of sequences upstream of the E1 protein. J Virol (1998) 1.09
The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS (2001) 1.09
Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat (2009) 1.08
A SIMPLE DILATOMETER. Plant Physiol (1932) 1.06
Effect of a single ethanol exposure on HIV replication in human lymphocytes. J Investig Med (1997) 1.05
Hepatitis C virus (HCV) infection and cryoglobulinemia: analysis of whole blood and plasma HCV-RNA concentrations and correlation with liver histology. Hepatology (2000) 1.05
Potential for development of antibiotic resistance in pathogenic treponemes. Rev Infect Dis (1985) 1.04
Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis (1992) 1.04
Evidence for neuroinflammation and neuroprotection in HCV infection-associated encephalopathy. Gut (2010) 1.04
Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. J Viral Hepat (2012) 1.04
Mothers' experience with household roles and social support during the first postpartum year. Women Health (1994) 1.01
The hepatitis A virus polyprotein expressed by a recombinant vaccinia virus undergoes proteolytic processing and assembly into viruslike particles. J Virol (1991) 1.00
Effect of primer selection on estimates of GB virus C (GBV-C) prevalence and response to antiretroviral therapy for optimal testing for GBV-C viremia. J Clin Microbiol (2006) 0.99
Physicians' effectiveness in assessing risk for human immunodeficiency virus infection. Arch Intern Med (1991) 0.99
Older persons' opinions about life-sustaining procedures in the face of dementia. Arch Fam Med (1999) 0.99
Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication. Clin Microbiol Infect (2004) 0.97
Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transpl Surg (1996) 0.95
Effect of interferon therapy on hepatitis C virus RNA in whole blood, plasma, and peripheral blood mononuclear cells. Hepatology (1998) 0.95
Hepatitis B virus mutations in the pre-S genome before and after liver transplantation. Hepatology (1996) 0.94
Synthesis of immunogenic hepatitis A virus particles by recombinant baculoviruses. Vaccine (1993) 0.93
Localization and behaviors in null mice suggest that ASIC1 and ASIC2 modulate responses to aversive stimuli. Genes Brain Behav (2013) 0.93
T cells and HIV-induced T cell syncytia exhibit the same motility cycle. J Leukoc Biol (1995) 0.93
[Acute hepatitis B: is antiviral therapy indicated? Two case reports]. Dtsch Med Wochenschr (2008) 0.91
Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases. Am J Med (1999) 0.90
The pre-S region determines the intracellular localization and appearance of hepatitis B virus. Hepatology (1999) 0.90
Fluorescence-based quantitative methods for detecting human immunodeficiency virus type 1-induced syncytia. J Clin Microbiol (2000) 0.90
Induction of hepatitis C virus (HCV)-specific T cells by needle stick injury in the absence of HCV-viraemia. Eur J Clin Invest (2007) 0.89
Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians. HIV Med (2006) 0.89
Presumed cryptogenic liver disease in Germany: High prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology. Z Gastroenterol (2009) 0.88
Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area. Liver (2000) 0.88
Elevated bound leptin correlates with energy expenditure in cirrhotics. Gastroenterology (2000) 0.88
HIV-induced syncytia in peripheral blood cell cultures crawl by extending giant pseudopods. Cell Immunol (1995) 0.87
The enhancer I core region contributes to the replication level of hepatitis B virus in vivo and in vitro. J Virol (2000) 0.87
Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. Z Gastroenterol (2004) 0.86
Serological pattern of hepatitis C virus recurrence after liver transplantation. J Hepatol (1996) 0.85
Different patterns of decompensation in patients with alcoholic vs. non-alcoholic liver cirrhosis. Aliment Pharmacol Ther (2012) 0.85
Hepatitis C and the leptin system: bound leptin levels are elevated in patients with hepatitis C and decrease during antiviral therapy. Scand J Gastroenterol (2001) 0.85
Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine. Vaccine (1999) 0.84
Analysis of hepatitis C virus genome in patients with autoimmune hepatitis type 2. Gastroenterology (1994) 0.83
Cure of mucormycosis in a renal transplant patient receiving ciclosporin with maintenance of immunosuppression. Am J Nephrol (1988) 0.83
Risk factors for hepatitis C fibrosis: a prospective study of United States veterans compared with nonveterans. J Viral Hepat (2007) 0.83
Effects of irradiation on mixed müllerian tumors of the uterus. Cancer (1979) 0.83
Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis. J Viral Hepat (2011) 0.83
Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant (2012) 0.83
HBV-specific T-cell responses in healthy seronegative sexual partners of patients with chronic HBV infection. J Viral Hepat (2009) 0.82
Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C? Clin Nephrol (2005) 0.81
Famciclovir treatment of chronic hepatitis B in heart transplant recipients: a prospective trial. Transplantation (1999) 0.81
Transmission of GB virus type C via transfusion in a cohort of HIV-infected patients. J Infect Dis (2012) 0.81
[Prevalence of hepatitis B in pregnancy and selective screening]. Geburtshilfe Frauenheilkd (1996) 0.81
[Coinfection of hepatitis B and C in HIV-infected patients]. Wien Med Wochenschr (1997) 0.81
New hepatitis viruses. J Hepatol (1996) 0.81
Optimum experimental designs for properties of a compartmental model. Biometrics (1993) 0.81
Autologous blood donor screening indicated a lower prevalence of viral hepatitis in East vs West Germany: epidemiological benefit from established health resources. J Viral Hepat (2009) 0.80
GB virus C infection among young, HIV-negative injection drug users with and without hepatitis C virus infection. J Viral Hepat (2011) 0.80
New distribution record for Dermacentor hunteri Bishopp (Acari: Ixodidae). J Med Entomol (1976) 0.80
Acoustic radiation force impulse (ARFI) elastography in acute liver failure: necrosis mimics cirrhosis. Z Gastroenterol (2011) 0.80
Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial. J Viral Hepat (2013) 0.79
Recombinant hepatitis A virus antigen: improved production and utility in diagnostic immunoassays. J Clin Microbiol (1998) 0.79
Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy. J Viral Hepat (2006) 0.79
Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C. J Viral Hepat (2011) 0.79
Risk factors and prevalence of hepatitis E in German immigrants from the former Soviet Union. J Med Virol (1995) 0.79
Successful liver transplantation in antituberculosis therapy-induced acute fulminant hepatic failure. Transplant Proc (2009) 0.79
Impact of GB virus type C infection on mother-to-child HIV transmission in the Women and Infants Transmission Study Cohort. HIV Med (2007) 0.79
A Bayesian stopping rule for a single arm study: With a case study of stem cell transplantation. Stat Med (2006) 0.79
Relationship between human leukocyte antigen determinants and courses of hepatitis B virus infection in Caucasian patients with end-stage renal disease. Scand J Gastroenterol (1996) 0.79
Sorption-desorption of carbamazepine from irrigated soils. J Environ Qual (2006) 0.79
Poor correlation between published methods to predict creatinine clearance and measured creatinine clearance in asymptomatic HIV infected individuals. Ren Fail (1998) 0.78
Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only. Transpl Infect Dis (2010) 0.78
Impaired TRAIL-dependent cytotoxicity of CD1c-positive dendritic cells in chronic hepatitis C virus infection. J Viral Hepat (2008) 0.78